Synthetic lethality as a basis to select drug combinations
Update: 2017-07-31
Description
Prof Bernards speaks with ecancer at WIN 2017 about a staggered '1-2 punch' treatment schedule of cancer therapies, built on synthetic lethality.
In the case of BRAF melanoma, he describes the acquired MEK-resistance of tumour cells following initial treatments exposes vulnerability to histone deacetylases (HDAC) which generate a toxic level of reactive oxygen species (ROS) in cancer cells.
Prof Bernards outlines how intermittent dosing cycles with short HDAC therapies 'chasers' may prevent further resistance development and extend patient survival.
He goes on to explain the best treatment window for selectively targeting cancer cells follows an induced senescence, with animal models currently in development.
In the case of BRAF melanoma, he describes the acquired MEK-resistance of tumour cells following initial treatments exposes vulnerability to histone deacetylases (HDAC) which generate a toxic level of reactive oxygen species (ROS) in cancer cells.
Prof Bernards outlines how intermittent dosing cycles with short HDAC therapies 'chasers' may prevent further resistance development and extend patient survival.
He goes on to explain the best treatment window for selectively targeting cancer cells follows an induced senescence, with animal models currently in development.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
